title: Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
authors: Discovery Chemistry, Drug Metabolism and Pharmacokinetics, Drug Safety, and Metabolic & Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, USA. guixue.yu@bms.com
authors: G
authors: G
authors: Yu
authors: H J
authors: HJ
authors: Mason
authors: X
authors: X
authors: Wu
authors: J
authors: J
authors: Wang
authors: S
authors: S
authors: Chong
authors: G
authors: G
authors: Dorough
authors: A
authors: A
authors: Henwood
authors: R
authors: R
authors: Pongrac
authors: L
authors: L
authors: Seliger
authors: B
authors: B
authors: He
authors: D
authors: D
authors: Normandin
authors: L
authors: L
authors: Adam
authors: J
authors: J
authors: Krupinski
authors: J E
authors: JE
authors: Macor
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000818:Animals; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004285:Dogs; D007172:Erectile Dysfunction / Q000188:drug therapy; D066298:In Vitro Techniques; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D010413:Penis / Q000187:drug effects / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517384:Pde5a protein, rat